Prognostic Value of a Proliferation Signature in Cancer
Author Information
Author(s): Starmans M H W, Krishnapuram B, Steck H, Horlings H, Nuyten D S A, van de Vijver M J, Seigneuric R, Buffa F M, Harris A L, Wouters B G, Lambin P
Primary Institution: Maastricht Radiation Oncology (Maastro), GROW Research Institute, University of Maastricht
Hypothesis
Derivation of a specific in vitro-derived signature based solely on proliferation may provide valuable information on tumour status, prognosis and outcome prediction across diverse tumour types.
Conclusion
The proliferation signature has a high prognostic value and the potential to be converted into a predictive test for patient selection in cancer treatment.
Supporting Evidence
- The proliferation signature was tested in five large clinical microarray data sets.
- One of the signatures had significant prognostic value in all data sets.
- Stratifying patients resulted in a clear difference in survival.
Takeaway
Researchers created a special test to see how fast cancer cells grow, which can help doctors predict how well patients will do and choose the best treatments.
Methodology
The study involved compiling two proliferation signatures from published microarray studies and testing their prognostic value in five large clinical microarray data sets.
Limitations
The study primarily relies on in vitro data, which may not fully represent in vivo conditions.
Participant Demographics
Patients included had breast, renal, or lung cancer.
Statistical Information
P-Value
<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website